The intra-aortic balloon counterpulsation affects patients through a combination of coronary flow improvement and afterload reduction. It has been the subject matter of several studies, but its benefit as mechanical support has not been proven. This work aims to prove the benefits of balloon counterpulsation in patients with ST-segment elevation acute myocardial infarction who, after<a href="https://solaci.org/en/2018/05/31/europcr-2018-semper-fi-the-reemergence-of-the-intra-aortic-balloon-counterpulsation/" title="Read more" >...</a>
EuroPCR 2018 | DESSOLV III: Bioabsorbable vs. Durable Polymer at 2 Years
Most drug-eluting stents are coated by a polymer that is used to contain the antiproliferative drug. Once the drug is released, the polymer remains in place and its presence has been associated with inflammation, restenosis, and neoatherosclerosis. The MiStent device features a polymer that becomes bioabsorbable once the drug has been released, which could, theoretically,<a href="https://solaci.org/en/2018/05/31/europcr-2018-dessolv-iii-bioabsorbable-vs-durable-polymer-at-2-years/" title="Read more" >...</a>
EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time
The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,<a href="https://solaci.org/en/2018/05/31/europcr-2018-swedish-registry-on-the-synergy-des-tested-in-primary-pci-for-the-first-time/" title="Read more" >...</a>
EuroPCR 2018 | FFR Reduces Death and Infarction Rates Compared with Medical Treatment
Pooled data from the most important recently published studies (FAME 2, Compare-Acute, and DANAMI3-PRIMULTI) conclude that there is a significant difference in favor of fractional flow reserve (FFR) as regards hard endpoints. Coronary revascularization guided by FFR reduces the risk of death and infarction when compared with optimal medical treatment in patients with stable and<a href="https://solaci.org/en/2018/05/28/europcr-2018-ffr-reduces-death-and-infarction-rates-compared-with-medical-treatment/" title="Read more" >...</a>
EuroPCR 2018 | FAME 2: FFR Shows 5-Year Benefit for Hard Endpoints
After a 5-year follow-up, and for the first time, functional assessment with fractional flow reserve (FFR) showed clear benefit for a hard endpoint: acute myocardial infarction. Use of FFR in patients with stable coronary artery disease so as to identify hemodynamically significant lesions in order to restrict angioplasty treatment to them has long-term benefits compared<a href="https://solaci.org/en/2018/05/28/europcr-2018-fame-2-ffr-shows-5-year-benefit-for-hard-endpoints/" title="Read more" >...</a>
EuroPCR 2018 | ORBITA: The Link Between Ischemia and Symptoms Is Still Not Entirely Understood
Invasive physiology tests used in the ORBITA trial could not predict which patients would benefit from angioplasty more than placebo (sham procedure) in terms of the trial’s primary endpoint, improvement in exercise time. These data were presented at EuroPCR 2018 and published simultaneously in Circulation. Results encourage debate over the importance of ischemia reduction with angioplasty<a href="https://solaci.org/en/2018/05/24/europcr-2018-orbita-the-link-between-ischemia-and-symptoms-is-still-not-entirely-understood/" title="Read more" >...</a>
EuroPCR 2018 | SYNTAX III REVOLUTION: Excellent Correlation Between Angiography and Computerized Tomography in Patients with Left Main and Multivessel Disease
In patients with left main or three-vessel coronary disease, heart team decisions on revascularization strategy (angioplasty or surgery) may be made based solely on noninvasive computerized tomography (CT) angiography, since there is great correlation between its results and those determined by conventional angiography. For the SYNTAX III REVOLUTION study, Dr. Serruys and his colleagues randomized<a href="https://solaci.org/en/2018/05/24/europcr-2018-syntax-iii-revolution-excellent-correlation-between-angiography-and-computerized-tomography-in-patients-with-left-main-and-multivessel-disease/" title="Read more" >...</a>
EuroPCR 2018 | SCAAR Registry at 10 years: FFR improves decision making in the long term
The SCAAR registry aimed at showing the differences in mortality at very long term when using functional assessment of coronary lesions (with FFR or iFR) in patients with chronic stable angina. The study compared 3460 patients assessed with FFR/iFR against 21221 patients undergoing PCI based on angiography, between January 2005 and March 2015. As<a href="https://solaci.org/en/2018/05/24/europcr-2018-scaar-registry-at-10-years-ffr-improves-decision-making-in-the-long-term/" title="Read more" >...</a>
Maintaining Physical Activity After an Acute Myocardial Infarction Reduces Mortality
Performing a successful primary angioplasty and prescribing preventive medication without advising on the importance of keeping up with or taking up physical activity is a waste of one of our many opportunities to improve the quality of life of our patients and reduce mortality among them. If clinical cardiologists do not take over the patient,<a href="https://solaci.org/en/2018/05/17/maintaining-physical-activity-after-an-acute-myocardial-infarction-reduces-mortality/" title="Read more" >...</a>
Restenosis Does Not Seem as Benign as We Thought
Elective, uncomplicated repeat revascularization after stent restenosis is associated with higher mortality rates according to a new meta-analysis that will be published soon in J Am Coll Cardiol Intrv. Historically, interventional cardiologists have seen target lesion revascularization (TLR) as a procedure that “unjustly” increased combined events in clinical studies and our own databases, thus representing<a href="https://solaci.org/en/2018/05/16/restenosis-does-not-seem-as-benign-as-we-thought/" title="Read more" >...</a>